# Hospital Universitario Fundación Jiménez Díaz

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/hospital-universitario-fundacion-jimenez-diaz/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 50.6 |
| Citations | 1,213,145 |
| City | Madrid |
| Country | ES |
| Description | Hospital Universitario Fundación Jiménez Díaz is a research organisation in Madrid, ES. OpenAlex records 18,985 works and 1,213,145 citations for it. 5,716 researchers list it as their most recent affiliation. |
| Homepage | http://www.fjd.es/ |
| OpenAlex ID | https://openalex.org/I4210129357 |
| Region | Madrid |
| Researchers | 5,716 |
| ROR ID | https://ror.org/049nvyb15 |
| Type | healthcare |
| Works | 18,985 |

## University papers

Showing 12 of 31.

- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/)
- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/updated-analysis-from-keynote-189-pembrolizumab-or-placebo-plus-pemetrexed-and/)
- [Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study](https://scholariq.org/papers/pembrolizumab-plus-pemetrexed-and-platinum-in-nonsquamous-non-small-cell-lung/)
- [MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program](https://scholariq.org/papers/myc-bcl2-protein-coexpression-contributes-to-the-inferior-survival-of-activated/)
- [Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/five-year-outcomes-from-the-randomized-phase-iii-trials-checkmate-017-and-057/)
- [EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis](https://scholariq.org/papers/eular-recommendations-for-the-use-of-imaging-of-the-joints-in-the-clinical/)
- [Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial](https://scholariq.org/papers/adjuvant-osimertinib-for-resected-egfr-mutated-stage-ib-iiia-non-small-cell-lung/)
- [A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of Metastasis](https://scholariq.org/papers/a-high-throughput-study-in-melanoma-identifies-epithelial-mesenchymal-transition/)
- [Progression in Cutaneous Malignant Melanoma Is Associated with Distinct Expression Profiles](https://scholariq.org/papers/progression-in-cutaneous-malignant-melanoma-is-associated-with-distinct/)

## University researchers

- [Álvaro Villalba](https://scholariq.org/researchers/alvaro-villalba/)
- [Manuel Calduch Gargallo](https://scholariq.org/researchers/manuel-calduch-gargallo/)

## University top topics

Showing 8 of 25.

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.